Kaitlyn D’Onofrio

DocwireNews

<a href="https://www.docwirenews.com/condition-center/orthopedicscc/orthopedics-center-picks/how-has-the-covid-19-pandemic-impacted-spine-surgeons/">The COVID-19 pandemic</a> has led to cancelled surgeries, <a href="https://www.docwirenews.com/condition-center/orthopedicscc/orthopedics-center-picks/dementia-patients-have-poorer-surgery-outcomes-including-increased-mortality/">delayed treatments</a>, and patients hesitating to seek care. One concern has been the effect this may have on a patient&rsquo;s health down the road. For patients with ductal carcinoma in situ (DCIS) breast cancer, delaying surgery may not impact their overall survival, according to a study.&ldquo;The most pressing question today is what will surgical delays due to the pandemic mean for patient outcomes, and the reality is that we will only have the answers years from now,&rdquo; said lead study author Christina Minami, MD, MS, <a href="https://www.eurekalert.org/pub_releases/2020-08/bawh-sdf080620.php">in a press release</a>.&ldquo;In the meantime, these data should provide some reassurance and encouragement&mdash;they don&rsquo;t indicate that outcomes will be changed dramatically,&rdquo; continued Dr. Minami, a surgeon in the Division of Breast Surgery at the Brigham and Women&rsquo;s Hospital. &ldquo;But we do encourage patients to follow up with their surgeons on a care plan as COVID-19 surges grow or subside locally.&rdquo;Dr. Minami and colleagues queried the National Cancer Database to identify patients with DCIS or ER+ cT1-2N0 breast cancer treated between 2010 and 2016 to determine time to surgery. A total of 378,839 patients were analyzed; of those undergoing primary surgery, 98% had a time to surgery within 120 days. For cT1N0 and cT2N0 patients chosen for neoadjuvant endocrine therapy, among cT1N0 patients, 59.6% underwent surgery within 120 days, and among cT2N0 patients, 30.9% were operated on within 120 days. Time to surgery did not affect overall survival among DCIS or neoadjuvant endocrine therapy patients. In DCIS patients, a correlation was observed between increased time to surgery and greater pathological upstaging risk. When using &lt;60 days as a reference group, early-stage estrogen receptor-positive (ER+) patients who underwent surgery within 60 to 120 days had an odds ratio (OR) of 1.15 (95% confidence interval [CI], 1.08 to 1.22); patients whose time to surgery was &gt;120 days had an OR of 1.44 (95% CI, 1.24 to 1.68). For ER- patients, the OR for patients treated within &gt;120 days was 1.36 (95% CI, 1.01 to 1.82). No difference was observed for patients with invasive cancer, regardless of their initial treatment strategy.&ldquo;Anxiety for both surgeons and patients alike stems from the unknown&mdash;what does a delay in surgery mean for our patients?&rdquo; Dr. Minami said. &ldquo;We sought to help address questions about outcomes. Ideally, we&rsquo;d like to have randomized, controlled studies, but under the circumstances, we needed to take the more unconventional approach by looking at retrospective data.&rdquo;The study was published in the <a href="https://www.journalacs.org/article/S1072-7515(20)30544-5/fulltext">Journal of the American College of Surgeons</a>.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Is It Okay to Delay Surgery in Very Early Breast Cancer?

Breast Cancer News

The COVID-19 pandemic has led to cancelled surgeries, delayed treatments, and patients hesitating to seek care. One concern has been the effect this may have on a patient’s ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe